Question 1

What is Sol-Gel Technologies's P/E ratio?

Accepted Answer

Sol-Gel Technologies (SLGL) P/E ratio is 138.6× as of March 9, 2023. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Sol-Gel Technologies?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Sol-Gel Technologies specifically, the relevant sector benchmark is the current sector median of 25.0×.

Question 5

Is Sol-Gel Technologies's P/E ratio high or low?

Accepted Answer

Sol-Gel Technologies's P/E ratio of 138.6× is below its own 5-year average of 409.2× and above the sector median of 25.0×. That places the current reading at the 27th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Sol-Gel Technologies's historical P/E ratio range?

Accepted Answer

In the available daily series, Sol-Gel Technologies (SLGL) P/E ratio has ranged from a low of 89.5× in 2022 to a high of 836.7× in 2022. The 5-year average is 409.2× and the 5-year median is 355.2×.

Question 7

What was Sol-Gel Technologies's P/E ratio in 2021?

Accepted Answer

Sol-Gel Technologies (SLGL) P/E ratio at the end of 2021 was 530.6×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Sol-Gel Technologies's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$117.40M	−$6.13M	—	—	Dec 31, 2025
2024	$259.08M	−$10.58M	—	—	Dec 31, 2024
2023	$309.22M	−$47.65M	—	—	Dec 31, 2023
2022	$1.05B	−$12.64M	—	—	Dec 31, 2022
2021	$1.71B	$3.22M	530.6×	—	Dec 31, 2021
2020	$2.23B	−$29.29M	—	—	Dec 31, 2020
2019	$3.51B	−$24.61M	—	—	Dec 31, 2019
2018	$1.14B	−$32.20M	—	—	Dec 31, 2018
2017	$2.45B	−$31.57M	—	—	Dec 31, 2017
2016	$2.45B	−$20.77M	—	—	Dec 31, 2016


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
UnitedHealth Group (UNH)	20.4×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
HCA Healthcare (HCA)	15.8×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Elevance Health (ELV)	12.3×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Sol-Gel Technologies (SLGL)

P/E Ratio daily chart for Sol-Gel Technologies (SLGL)

Historical P/E Ratio for Sol-Gel Technologies (SLGL) from 2016 to 2025

About P/E Ratio at Sol-Gel Technologies (SLGL)

Sol-Gel Technologies P/E Ratio by Year

Sol-Gel Technologies P/E Ratio 2021: 530.6×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Sol-Gel Technologies (SLGL) Key Financials

P/E Ratio daily chart for Sol-Gel Technologies (SLGL)

Historical P/E Ratio for Sol-Gel Technologies (SLGL) from 2016 to 2025

About P/E Ratio at Sol-Gel Technologies (SLGL)

Sol-Gel Technologies P/E Ratio by Year

Sol-Gel Technologies P/E Ratio 2021: 530.6×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

+What is Sol-Gel Technologies's P/E ratio?

+How is the P/E ratio calculated?

+What is the P/E ratio?

+What is a good P/E ratio for Sol-Gel Technologies?

+Is Sol-Gel Technologies's P/E ratio high or low?

+What is Sol-Gel Technologies's historical P/E ratio range?

+What was Sol-Gel Technologies's P/E ratio in 2021?

+Why does Sol-Gel Technologies's P/E ratio change over time?

Sol-Gel Technologies (SLGL) Key Financials